The Latest Breaking News from Amneal

Amneal Launches Its Generic Lanreotide Immediately While the Brand Still Posts Nearly a Billion in US Sales

FDA cleared Amneal's generic lanreotide, and it launched immediately. Why more competition has not yet cut what patients pay for monthly injections.

Medical Daily · Sep 20

Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase

Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches. Speaking at a Gol

MarketBeat · Jun 9

3 Lesser-Known Healthcare Names With Major Upside in Store

These are three healthcare stocks offering a compelling combination of secure business, strong fundamentals, and growth opportunity.

MarketBeat · Oct 2, 2025